Department of Cardiology, Beijing Anzhen Hospital, Beijing, China.
Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing, China.
J Clin Hypertens (Greenwich). 2020 Nov;22(11):1968-1973. doi: 10.1111/jch.14030. Epub 2020 Sep 10.
Hypertension is an important cause of cerebral small vessel disease, especially of white matter hyperintensity (WMH). The ability of intensive blood pressure (BP) control in preventing this pathological progression remains unclear. The authors systematically searched PubMed, EMBASE, SCOPUS, and Cochrane library for publications until July 20, 2020. Studies included were clinical trials with random allocation to an antihypertensive medication against placebo, or different treatment targets. The primary outcome was intergroup differences in the change of WMH volume. A random-effect model was applied for pooling effect measures. Subgroup analysis and meta-regression were conducted to explore heterogeneity. Seven studies with 2693 patients were identified. Compared with the control group, patients in the intensive BP control group had a slower progression of WMH, with a pooled intergroup standard mean difference (SMD) for WMH change of -0.22 (95% CI: -0.35 ~ -0.09, I = 63%). For studies comparing intensive and standard BP target, the pooled SMD is -0.37 (95% CI:-0.50~-0.24, I = 0%), while the pooled SMD of studies comparing active antihypertensive medication and placebo was only -0.08 (95% CI: -0.17 ~ 0.01, I = 0%). Meta-regression analysis showed that the reduction in WMH progression is proportional to the magnitude of intensive BP control (β = -0.028, P < .001). In conclusion, intensive BP control prevents WMH progression, and its effect is associated with the magnitude of intensive BP control.
高血压是脑小血管病的重要病因,尤其是脑白质高信号(WMH)。强化血压(BP)控制预防这种病理进展的能力尚不清楚。作者系统地检索了 PubMed、EMBASE、SCOPUS 和 Cochrane 图书馆截至 2020 年 7 月 20 日的出版物。纳入的研究为随机分配抗高血压药物与安慰剂或不同治疗靶点的临床试验。主要结局为 WMHg 量变化的组间差异。应用随机效应模型进行汇总效应测量。进行亚组分析和荟萃回归以探索异质性。确定了 7 项纳入 2693 例患者的研究。与对照组相比,强化 BP 控制组的 WMHg 进展较慢,WMHg 变化的组间标准均数差(SMD)为 -0.22(95%CI:-0.35-0.09,I=63%)。对于比较强化和标准 BP 目标的研究,汇总 SMD 为-0.37(95%CI:-0.50-0.24,I=0%),而比较积极降压药物与安慰剂的研究的汇总 SMD 仅为-0.08(95%CI:-0.17~0.01,I=0%)。荟萃回归分析表明,WMHg 进展减少与强化 BP 控制的幅度成正比(β=-0.028,P<0.001)。总之,强化 BP 控制可预防 WMHg 进展,其效果与强化 BP 控制的幅度相关。